Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 87; no. 2; pp. 122 - 129
• Main Authors: Jurmeister, Philipp, Lenze, Dido, Berg, Erika, Mende, Stefanie, Schäper, Frank, Kellner, Udo, Herbst, Hermann, Sers, Christine, Budczies, Jan, Dietel, Manfred, Hummel, Michael, von Laffert, Maximilian
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.02.2015
• Subjects: Adult; Aged; Aged, 80 and over; ALK; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - genetics; Early Detection of Cancer; Female; FISH; Genetic Variation; Hematology, Oncology and Palliative Medicine; Humans; IHC; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Male; MET; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Non-small cell lung cancer; Predictive biomarkers; Prognosis; Protein-Tyrosine Kinases - genetics; Protein-Tyrosine Kinases - metabolism; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Proto-Oncogene Proteins c-met - genetics; Proto-Oncogene Proteins c-met - metabolism; Pulmonary/Respiratory; Receptor Protein-Tyrosine Kinases - genetics; Receptor Protein-Tyrosine Kinases - metabolism; ROS1; Targeted therapy; ALK; IHC; Targeted therapy; Predictive biomarkers; Non-small cell lung cancer; FISH; MET; ROS1
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2014.11.018

Highlights • This is the first report on parallel FISH and IHC screening for ALK, MET and ROS1. • Concordant results for ALK IHC and ALK FISH were seen in all cases. • MET FISH and IHC showed discordant results in 10.0% of cases. • MET overexpression can occur in ALK rearranged tumors. • Besides rearrangements, ROS1 amplifications can also occur in NSCLCs.